We are a drug discovery company selectively targeting protein myristoylation for the treatment of a wide range of diseases including cancer and viral infections. Based on our world leading research into the structure and biology of N-myristoyltransferase (NMT), the key enzyme in protein myristoylation we have made highly potent and selective small molecule inhibitors of this enzyme. Led by a team of internationally renowned scientists and drug developers with an outstanding track record of commercial and academic successes.